| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 17, 2010
MINNEAPOLIS, Mar 17, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced it has completed Pre-Market Approval (PMA) submission in consideration for U.S. Food and Drug...
-
Mar 16, 2010Partnerships with American College of Cardiology and Association of Black Cardiologists and Latest Data from IMPROVE HF Clinical Study All Aim to Drive Equitable Treatment
MINNEAPOLIS & ATLANTA, Mar 16, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today introduced Every Patient First, a health equity initiative that, in partnership with health care providers,...
-
Mar 15, 2010Late Breaking Clinical Trial at 59th Annual Scientific Session of the American College of Cardiology (ACC) also Showed Shortened Cardiovascular Hospital Stays
MINNEAPOLIS & ATLANTA, Mar 15, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE: MDT) today announced results from the CONNECT trial showing the median time to clinical decision was significantly...
-
Mar 15, 2010Safety and Effectiveness Trial Evaluated the Arctic Front(R) Cardiac CryoAblation Catheter System for the Treatment of Paroxysmal Atrial Fibrillation
MINNEAPOLIS & ATLANTA, Mar 15, 2010 (BUSINESS WIRE) -- Medtronic, Inc. (NYSE:MDT) today announced data from the STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial...
-
Mar 14, 2010Independent Analysis of Large and Comprehensive ENDEAVOR Program Shows Remarkably Durable Safety and Efficacy at Five Years of Follow Up in Coronary Artery Disease Patients
MINNEAPOLIS & ALTANTA, Mar 14, 2010 (BUSINESS WIRE) -- The consistency and quality of the long-term clinical results for the Endeavor(R) drug-eluting stent (DES) from Medtronic, Inc. (NYSE: MDT),...